Since the introduction of the AMNOG in 2011 in Germany, we provide our clients with comprehensive advice and support on all biostatistical issues concerning German benefit dossiers. We develop strategies to meet the requirements of IQWiG and the G-BA and at the same time achieve the best possible result for your product.
Over 25 biostatisticians support you in all statistical aspects during the entire benefit assessment process.
- direct and indirect comparisons (adjusted/non-adjusted, historical and external control groups)
- (Network) meta-analyses
- Propensity score matching
- Matching-adjusted indirect comparisons (MAIC)
- Surrogate validations
- Survival time analyses
- Multiple regression
- ...and other methods. Feel free to contact us!
- Additional Analyses
For your benefit dossier, we carry out all additionally required statistical analyses according to the current requirements of IQWiG and G-BA and support you in communicating with your global colleagues.
- Data Visualization (ShinyViz)
Fast visualization and individualized graphical presentation of analysis results to determine the best possible dossier strategy.
- routine practice data collection (AbD)
We create the SAP and the study protocol with you. We are at your side with advice and support throughout the entire AbD process.
- European HTA
At AMS, we have been active in the field of EU HTA since 2015. Among other things, we support you in statistical evaluations around JSCs, rapid REAs and JCAs.